), a global leader in medical devices used in critical care and
surgery, recently announced the U.S. Food and Drug Administration
(FDA) 510(k) clearance to market its pressure injectable Arrow PICC
preloaded with Arrow VPS Vascular Positioning System Stylet.
According to the company, Arrow VPS with real-time intravascular
Doppler, ECG and advanced algorithmic logic allows clinicians to
discard the otherwise mandatory chest X-ray. It also saves loading
time for the catheter. The Arrow PICC powered by Arrow VPS Stylet
is designed to meet the changing needs of clinicians by curtailing
the risk of infection and unforeseen needle sticks at
Teleflex's newest Arrow PICC will enhance its line of vascular
access products in its largest segment - Critical Care. Revenues
from the Critical Care segment edged up 0.2% year over year to
$254.1 million (66% of the total revenues) in the second quarter.
Higher sales for vascular access products along with anesthesia and
urology products led to segment growth.
Management believes that performance in the most recent quarter
validates the company's focus on boosting top-line growth and
enhancing its product portfolio. Teleflex continues to build its
Arrow brand to strengthen its Critical Care franchise. The Arrow
line of products is currently the company's foremost brand.
Earlier this month, Teleflex was awarded an innovative
technology agreement by Novation for the Arrow VPS Vascular
Positioning System. The agreement, effective from September 1,
2012, encompasses the VPS console and stylets, as well as
pre-loaded stylets. It is binding through three years.
Limerick, Pennsylvania-based Teleflex' focus on profitable and
consistent growth is expected to yield results, helped by
demographic trends and barriers to entry in the industry. The
recent divestiture of its OEM Orthopedic division is expected to
aid the company's strategy of new product introduction, and
investment in innovative technologies. This might accelerate
Teleflex's top-line in the years ahead.
), which operate in similar business segments, present a tough
competitive landscape for Teleflex. Additionally, the company
operates in a stringent regulatory environment. The demand for its
products is susceptible to healthcare reimbursement systems in the
domestic as well as the international market.
Teleflex currently retains a Zacks #3 Rank, which translates
into a short-term Hold rating.
BARD C R INC (BCR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.